CN Patent

CN110317168A — 一种博舒替尼的纯化方法

Assigned to Chia Tai Tianqing Pharmaceutical Group Co Ltd · Expires 2019-10-11 · 7y expired

What this patent protects

本发明提供了一种博舒替尼的纯化方法，包括：1)将博舒替尼粗品溶于乙腈‑水混合溶剂；(2)任选地，活性炭脱色，过滤，获得滤液；(3)降温，析晶，过滤，干燥，获得博舒替尼纯化品。本发明提供的纯化方法可以代替柱层析纯化方法或制备色谱纯化方法，去除博舒替尼粗品中直接采用惯常的结晶方法而难以纯化的杂质，需要的溶剂量小，且操作工艺简便，纯化收率和产品纯度均较高，有利于工业化生产。

USPTO Abstract

本发明提供了一种博舒替尼的纯化方法，包括：1)将博舒替尼粗品溶于乙腈‑水混合溶剂；(2)任选地，活性炭脱色，过滤，获得滤液；(3)降温，析晶，过滤，干燥，获得博舒替尼纯化品。本发明提供的纯化方法可以代替柱层析纯化方法或制备色谱纯化方法，去除博舒替尼粗品中直接采用惯常的结晶方法而难以纯化的杂质，需要的溶剂量小，且操作工艺简便，纯化收率和产品纯度均较高，有利于工业化生产。

Drugs covered by this patent

bosutinib-monohydrate (BOSUTINIB MONOHYDRATE)

Patent Metadata

Patent number: CN110317168A
Jurisdiction: CN
Classification: —
Expires: 2019-10-11
Drug substance claim: No
Drug product claim: No
Assignee: Chia Tai Tianqing Pharmaceutical Group Co Ltd
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.